Optic Neuritis

Categories: Eye diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Optic Neuritis

MalaCards integrated aliases for Optic Neuritis:

Name: Optic Neuritis 12 74 20 36 54 6 44 15 17 71 32


External Ids:

Disease Ontology 12 DOID:1210
KEGG 36 H01717
ICD9CM 34 377.3
MeSH 44 D009902
NCIt 50 C84950
SNOMED-CT 67 194051001
ICD10 32 H46
UMLS 71 C0029134

Summaries for Optic Neuritis

KEGG : 36 Optic neuritis is a demyelinating inflammatory disease of the optic nerve that presents with an abrupt loss of vision. The majority of patients are between the ages of 20 and 50 years, with a mean age ranging from 30 to 35 years. It occurs more commonly in women than in men. The onset is usually with pain on eye movement in one eye and subacute visual loss. One-third of patients have a mildly edematous optic disc. The visual disturbance resolves in 95% of cases. Many cases of optic neuritis are associated with multiple sclerosis or neuromyelitis optica or can occur in isolation. Occasionally, optic neuritis can result from infectious processes involving the paranasal sinuses or occur in the course of a systemic viral infection. High-dosed intravenous methylprednisolone therapy speeds recovery but does not improve the final outcome. For patients judged to be at high risk of developing multiple sclerosis, immune prophylaxis with beta-interferon or glatiramer acetate is recommended.

MalaCards based summary : Optic Neuritis is related to autoimmune optic neuritis and neuromyelitis optica, and has symptoms including eye manifestations An important gene associated with Optic Neuritis is AQP4 (Aquaporin 4), and among its related pathways/superpathways are PEDF Induced Signaling and Akt Signaling. The drugs Prednisone and Glatiramer Acetate have been mentioned in the context of this disorder. Affiliated tissues include optic nerve which may cause a complete, eye and brain, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 An optic nerve disease that results in inflammation located in optic nerve which may cause a complete or partial loss of vision.

GARD : 20 Optic neuritis is inflammation of the optic nerve, the nerve that carries the visual signal from the eye to the brain. The condition may cause sudden, reduced vision in the affected eye(s). While the cause of optic neuritis is unknown, it has been associated with autoimmune diseases, infections, multiple sclerosis, drug toxicity and deficiency of vitamin B-12. Vision often returns to normal within 2-3 weeks without treatment. In some cases, corticosteroids are given to speed recovery. If known, the underlying cause should be treated.

Wikipedia : 74 Optic neuritis describes any condition that causes inflammation of the optic nerve; it may be associated... more...

Related Diseases for Optic Neuritis

Diseases in the Optic Neuritis family:

Autoimmune Optic Neuritis

Diseases related to Optic Neuritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 925)
# Related Disease Score Top Affiliating Genes
1 autoimmune optic neuritis 32.2 MOG MBP DPYSL5 CNTF AQP4
2 neuromyelitis optica 32.1 MOG MBP IL6 IL1B HLA-DRB1 GFAP
3 allergic encephalomyelitis 31.8 PLP1 MOG MBP
4 acute retrobulbar neuritis 31.4 MT-ND4 MBP AQP4
5 scotoma 31.4 MT-ND6 MT-ND4 AQP4
6 chickenpox 31.2 TNF IL6 IL10
7 measles 31.1 TNF IL6 IL1B HLA-DRB1
8 herpes zoster 31.0 TNF IL10 HLA-DRB1 CCR5
9 miller fisher syndrome 30.8 TNF MAG AQP4
10 lyme disease 30.8 TNF IL6 IL1B HLA-DRB1
11 guillain-barre syndrome 30.8 TNF MPZ MOG MBP HLA-DRB1
12 acute disseminated encephalomyelitis 30.8 MPZ MOG MBP IL1B IL10 HLA-DRB1
13 sarcoidosis 1 30.8 TNF LTA IL1B HLA-DRB1 CCR5
14 meningoencephalitis 30.7 TNF MBP IL6 IL10 BDNF
15 internuclear ophthalmoplegia 30.7 MOG MBP DPYSL5 AQP4
16 neurosyphilis 30.7 IL10 CXCL8
17 polyradiculoneuropathy 30.7 MPZ MBP IL10
18 cytomegalovirus retinitis 30.7 TNF IL10 HLA-DRB1 CCR5
19 iridocyclitis 30.6 TNF IL6 IL1B IL10
20 arachnoiditis 30.6 TNF IL1B AQP4
21 posterior uveitis 30.6 TNF LTA IL6
22 chorioretinitis 30.6 TNF IL6 IL1B IL10
23 myelitis 30.6 TNF MOG MBP IL6 IL10 DPYSL5
24 myasthenia gravis 30.6 TNF PLP1 MBP LTA IL10
25 rubella 30.6 TNF MOG IL6 IL1B IL10 HLA-DRB1
26 panuveitis 30.6 TNF IL6 IL10 HLA-DRB1
27 chronic inflammatory demyelinating polyradiculoneuropathy 30.5 MPZ MBP IL10 HLA-DRB1
28 transverse myelitis 30.5 TNF MOG MBP IL6 IL10 CXCL8
29 wallerian degeneration 30.5 MPZ MAG CNTF
30 hepatitis a 30.5 TNF IL1B IL10
31 multifocal choroiditis 30.5 TNF IL10
32 iritis 30.5 TNF IL6 IL10
33 intracranial hypertension 30.4 TNF IL1B AQP4
34 q fever 30.4 TNF IL6 IL1B IL10
35 macular retinal edema 30.4 TNF IL6 IL1B CXCL8
36 mononeuropathy 30.4 TNF MPZ MAG
37 secondary progressive multiple sclerosis 30.4 MBP IL10 CCR5 BDNF
38 scrub typhus 30.4 TNF IL1B IL10
39 exanthem 30.4 TNF IL6 IL1B IL10 CXCL8
40 aseptic meningitis 30.3 TNF IL1B IL10 CXCL8
41 acquired immunodeficiency syndrome 30.3 TNF MBP IL6 IL1B IL10 CCR5
42 typhoid fever 30.3 TNF LTA IL6 IL1B HLA-DRB1
43 oligoarticular juvenile idiopathic arthritis 30.3 TNF HLA-DRB1 CCR5
44 spondylitis 30.3 TNF LTA IL6 IL1B IL10
45 subacute sclerosing panencephalitis 30.2 TNF MOG MBP IL6 IL10
46 brucellosis 30.2 TNF IL6 IL10 CXCL8
47 meningitis 30.2 TNF IL6 IL1B IL10 CXCL8 AQP4
48 crohn's colitis 30.2 TNF IL1B CXCL8
49 mumps 30.2 TNF IL6 IL1B IL10 HLA-DRB1 CXCL8
50 encephalitis 30.2 TNF MOG IL6 IL1B IL10 GFAP

Comorbidity relations with Optic Neuritis via Phenotypic Disease Network (PDN):

Hypertension, Essential Temporal Arteritis

Graphical network of the top 20 diseases related to Optic Neuritis:

Diseases related to Optic Neuritis

Symptoms & Phenotypes for Optic Neuritis

UMLS symptoms related to Optic Neuritis:

eye manifestations

MGI Mouse Phenotypes related to Optic Neuritis:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.37 AQP4 BDNF CCR5 CNTF DPYSL5 GFAP
2 homeostasis/metabolism MP:0005376 10.28 AQP4 BDNF CCR5 CNTF GFAP IL10
3 growth/size/body region MP:0005378 10.27 AQP4 BDNF GFAP IL10 IL1B IL6
4 cellular MP:0005384 10.26 BDNF CCR5 CNTF GFAP IL10 IL6
5 hematopoietic system MP:0005397 10.25 AQP4 CCR5 CNTF IL10 IL1B IL6
6 immune system MP:0005387 10.21 AQP4 CCR5 CNTF GFAP IL10 IL1B
7 nervous system MP:0003631 10.19 AQP4 BDNF CCR5 CNTF DPYSL5 GFAP
8 muscle MP:0005369 9.97 CCR5 CNTF GFAP IL10 IL6 MOG
9 reproductive system MP:0005389 9.85 BDNF CCR5 CNTF IL10 IL6 MBP
10 respiratory system MP:0005388 9.56 AQP4 BDNF CCR5 IL10 IL6 LTA
11 vision/eye MP:0005391 9.4 AQP4 BDNF CCR5 GFAP IL10 IL6

Drugs & Therapeutics for Optic Neuritis

Drugs for Optic Neuritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 68)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
Glatiramer Acetate Phase 4 147245-92-9 3081884
3 (T,G)-A-L Phase 4
4 Antineoplastic Agents, Hormonal Phase 4
5 Adrenocorticotropic Hormone Phase 4
Simvastatin Approved Phase 3 79902-63-9 54454
4-Aminopyridine Approved Phase 2, Phase 3 504-24-5 1727
Interferon beta-1b Approved Phase 2, Phase 3 145155-23-3
9 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
10 Hypolipidemic Agents Phase 3
11 Lipid Regulating Agents Phase 3
12 Anticholesteremic Agents Phase 3
13 Antibodies Phase 3
14 Immunoglobulins Phase 3
15 Hematinics Phase 3
16 Epoetin alfa Phase 3 113427-24-0
17 gamma-Globulins Phase 3
18 Immunoglobulins, Intravenous Phase 3
19 Rho(D) Immune Globulin Phase 3
20 Potassium Channel Blockers Phase 2, Phase 3
21 Fingolimod Hydrochloride Phase 2, Phase 3
Hydrochlorothiazide Approved, Vet_approved Phase 2 58-93-5 3639
Amiloride Approved Phase 2 2016-88-8, 2609-46-3 16231
Phenytoin Approved, Vet_approved Phase 2 57-41-0 1775
Histamine Approved, Investigational Phase 2 51-45-6, 75614-87-8 774
Clemastine Approved, Investigational Phase 2 15686-51-8 26987
Minocycline Approved, Investigational Phase 2 10118-90-8 5281021
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2 1406-16-2
Vitamin D3 Approved, Nutraceutical Phase 2 67-97-0 6221 5280795
31 Pharmaceutical Solutions Phase 2
32 Sodium Chloride Symporter Inhibitors Phase 2
33 Amiloride, hydrochlorothiazide drug combination Phase 2
34 Antihypertensive Agents Phase 2
35 Antibodies, Monoclonal Phase 2
36 Sodium Channel Blockers Phase 2
37 diuretics Phase 2
38 Diuretics, Potassium Sparing Phase 2
39 Anticonvulsants Phase 2
40 Calcium, Dietary Phase 2
41 Micronutrients Phase 2
42 Trace Elements Phase 2
43 Vitamin D2 Phase 2
44 Ergocalciferols Phase 2
45 Vitamins Phase 2
46 Nutrients Phase 2
47 Calciferol Phase 2
48 Histamine Antagonists Phase 2
49 Neurotransmitter Agents Phase 2
Histamine Phosphate Phase 2 51-74-1 65513

Interventional clinical trials:

(show top 50) (show all 71)
# Name Status NCT ID Phase Drugs
1 A Multicenter Longitudinal Cross-sectional Pilot Study, to Compare RNFL Thickness Measured by OCT After Treatment With Glatiramer or After no Treatment in Patients With CIS With or Without Optic Neuritis or With Early RRMS Unknown status NCT00910598 Phase 4 glatiramer acetate
2 Effect of High-Dose Prednisolone (Solu Dacortin®) Treatment on Choroidal and Optic Nerve Head Blood Flow in Humans Completed NCT00312325 Phase 4 Prednisolone
3 Controlled High-risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurologic Surveillance (CHAMPIONS10) Completed NCT00179478 Phase 4 interferon beta 1a 30 ug IM once weekly
4 A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis Recruiting NCT01838174 Phase 4 ACTHAR Gel (ACTH);IV methylprednisolone (steroids)
5 An Open Label Pilot Study of Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event: Comparison With CHAMPS Results. Withdrawn NCT00037115 Phase 4 interferon beta 1a;methotrexate;methylprednisolone
6 Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: a Pivotal Randomized Double Masked Placebo Controlled Study Unknown status NCT02220244 Phase 3 MD1003 100mg capsule
7 Simvastatin Treatment of Patients With Acut Optic Neuritis. A Doubleblind, Randomized and Placebo Controlled Fase III Trial Unknown status NCT00261326 Phase 3 simvastatin;placebo
8 Optic Neuritis Treatment Trial (ONTT) Unknown status NCT00000146 Phase 3 Methylprednisolone;Prednisone
9 Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial Completed NCT01962571 Phase 3 Erythropoietin alfa;Placebo
10 Intravenous Immunoglobulin Therapy in Optic Neuritis Completed NCT00000117 Phase 3 Immunoglobulin
11 Recovery of Demyelinating Optic Neuritis After Treatment With Equivalent High Doses of Oral vs. Intravenous Corticosteroids: a Randomized Single Blinded Clinical Trial Completed NCT01524250 Phase 2, Phase 3 corticosteroids;corticosteroids
12 A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON) Completed NCT00856635 Phase 3 Glatiramer Acetate;placebo
13 Dalfampridine After Optic Neuritis to Improve Visual Function in Multiple Sclerosis Completed NCT01337986 Phase 2, Phase 3 Dalfampridine/Placebo;Placebo/Dalfampridine
14 Phase II/III Study to Investigate the Effects of Fingolimod Versus Interferon Beta-1b on Visual Recovery After Optic Neuritis Terminated NCT01647880 Phase 2, Phase 3 Verum arm receiving Gilenya®;Active Comparator receiving Extavia®
15 A Randomised, Double-blind, Placebo-controlled Study of AIMSPRO in Treating Bladder Dysfunction in Secondary Progressive Multiple Sclerosis Unknown status NCT01228396 Phase 2 Hyperimmune caprine serum against HIV lysate
16 The Investigation Effect of Vitamin D on Retinal Changes in Patient With Optic Neuritis by Optic Coherence Tomography Unknown status NCT01465893 Phase 2 Vitamin D;Vitamin D withheld
17 A Randomized, Placebo-Controlled, Double-Blind, Phase IIa Study of Amiloride in the Treatment of Acute Autoimmune Optic Neuritis Unknown status NCT01879527 Phase 2 Amiloride hydrochlorothiazide;Sugar pill
18 A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With First Episode of Acute Optic Neuritis Completed NCT01721161 Phase 2 Placebo
19 A Double Blind Randomised Control Trial on Neuroprotection of Amiloride in Optic Neuritis Completed NCT01802489 Phase 2 Amiloride;Placebo
20 A Multicenter, Follow-Up Study to Assess Long-Term Electrophysiologic and Clinical Outcomes in Subjects Previously Enrolled in Study 215ON201 Completed NCT02657915 Phase 2 Placebo;BIIB033 100mg/Kg
21 Visual Reconstitution Therapy After Optic Neuritis Completed NCT01274702 Phase 2
22 Double Blind, Placebo-controlled Study to Determine the Safety and Efficacy of Erythropoietin as an add-on Therapy of Methylprednisolone in Subjects With Acute Optic Neuritis (VISION PROTECT) Completed NCT00355095 Phase 2 Erythropoietin
23 A Phase II Double Blind, Randomized, Placebo Controlled Trial of Neuroprotection With Phenytoin in Acute Optic Neuritis Completed NCT01451593 Phase 2 Phenytoin;Placebo
24 a Phase II Double Blind, Randomized, Placebo Controlled Trial of Effect of Phenytoin on the Ganglion Cell Inner Plexiform Layer (GCIPL) Thickness and Visual Field in Patients With a First Episode of Acute Optic Neuritis Completed NCT02939937 Phase 2 Phenytoin;placebo
25 A Phase II Trial of High-Dose Vitamin D Induction in Optic Neuritis (VitaDON 2) Recruiting NCT03302585 Phase 2 Vitamin D3;Placebo/Standard of Care Vitamin D3
26 A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Trial to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis Recruiting NCT02521311 Phase 2 Clemastine;Placebo
27 A Phase 2, Randomized, DB-PC, Parallel Group Study for the Treatment of Visual Pathway Deficits In Chronic Optic Neuropathy to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of CNM-Au8 For Remyelination In Multiple Sclerosis Recruiting NCT03536559 Phase 2 CNM-Au8;Placebo
28 Gypenosides Treatment for Optic Neuritis: a Randomised, Double-blind, Placebo-controlled Trial Active, not recruiting NCT02976766 Phase 2 Gypenosides;Placebo
29 A 48-week, Double-blind, Randomized, Multi-center, Parallel-group Study Comparing Structural Changes in the Retina and Evolution of Visual Function After Immediate Versus Delayed Treatment With Fingolimod in Patients With Acute Demyelinating Optic Neuritis Terminated NCT01757691 Phase 2 Fingolimod 0.5mg/daily;Placebo
30 A Two-arm, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Evaluate Safety and Tolerability and to Explore the Neuroprotective Effect of Atacicept as Assessed by Optical Coherence Tomography (OCT) in Subjects With Optic Neuritis (ON) as Clinically Isolated Syndrome (CIS) Over a 36-week Treatment Course Terminated NCT00624468 Phase 2 Atacicept;Placebo matched to atacicept
31 Developing Neuroprotection and Repair Strategies in MS: Phase IIa Randomized, Controlled Trial of Minocycline in Acute Optic Neuritis (ON) Terminated NCT01073813 Phase 2 Minocycline
32 A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II) Completed NCT01064505 Phase 1 QPI-1007 at various doses
33 Lipoic Acid as a Treatment for Acute Optic Neuritis: A Pilot Study Completed NCT01294176 Phase 1 Lipoic Acid
34 A Randomised, Double-blind, Placebo-controlled, Single (SAD) and Multiple Ascending Dose (MAD) Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BN201 in Healthy Subjects Completed NCT03630497 Phase 1 Comparison of BN201 treatment with Placebo
35 An Open-label Phase 1b Study of Avastin® (Bevacizumab) for the Treatment of Acute Optic Neuritis and/or Transverse Myelitis in Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD). Completed NCT01777412 Phase 1 Bevacizumab
36 Phase I, Single-Center, Open Label Trial of Ublituximab + Glucocorticoids for the Treatment of Acute Optic Neuritis and/or Transverse Myelitis in Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD) Completed NCT02276963 Phase 1 Ublituximab
37 Open Label Study of Safety and Tolerability of Rituximab in Neuromyelitis Optica, Recurrent Transverse Myelitis and Recurrent Bilateral Simultaneous Optic Neuritis Completed NCT00501748 Phase 1 Rituximab
38 A Randomized, Blinded, Parallel-Group, Phase 1 Study of Pharmacokinetics, Safety and Tolerability of Single Intravenous Doses of BIIB033 (Opicinumab ) Produced by 2 Manufacturing Processes, in Healthy Volunteers Completed NCT02833142 Phase 1 BIIB033 (opicinumab)
39 A Single Center Open Label Pilot Study of Alpha1-Antitrypsin: A Novel Treatment to Mitigate Neuromyelitis Optica Attacks Withdrawn NCT02087813 Phase 1 Alpha1-antitrypsin;methylprednisolone
40 Evaluation of Macular and Retinal Nerve Fiber Layer Thickness Measurements for Detection of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Optical Coherence Tomography. Unknown status NCT01024985
41 Linking Optic Nerve Lesion Length at MRI and the Retinal Axonal Loss at 12 Months From a Clinical Episode of Optic Neuritis Unknown status NCT03651362
42 The Effect of a Gluten Free Diet on the Permeability of the Blood Brain Barrier in Patients With Clinically Isolated Syndrome Measured by Dynamic Contrast Enhanced Magnetic Resonance Imaging Unknown status NCT03451955
43 The Correlation Between AQP-4 Ab and the Visual Function of Patients With Demyelinating ON at Onset Unknown status NCT02886377
44 Longitudinal Optic Neuritis Study (LONS) Unknown status NCT00000147 Methylprednisolone;Prednisone
46 Evaluation of the Effectiveness and Safety of Transcorneal Electrical Stimulation to Improve Visual Function After Ocular Trauma Completed NCT02019927
47 Retinal Thickness as a Potential Biomarker of Neurodegeneration and Early Cognitive Impairment in Patients With Multiple Sclerosis Completed NCT04153773
48 Outcomes of TLR-9 Antagonism in Steroid Resistant Optic Neuritis; A Pilot Study Completed NCT01424735 Mycobacterium w.(Mw)-freeze dried extract 0.5ml
49 Potential Neuroprotection With ACTHAR Following Acute Optic Neuritis Completed NCT01987167 Early Phase 1 ACTHAR
50 Interest of Dynamic Measures of the Pupil in Optic Neuritis Completed NCT02004054

Search NIH Clinical Center for Optic Neuritis

Cochrane evidence based reviews: optic neuritis

Genetic Tests for Optic Neuritis

Anatomical Context for Optic Neuritis

The Foundational Model of Anatomy Ontology organs/tissues related to Optic Neuritis:

Optic Nerve Which May Cause A Complete

MalaCards organs/tissues related to Optic Neuritis:

Eye, Brain, Retina, Spinal Cord, Pituitary, T Cells, Cortex

Publications for Optic Neuritis

Articles related to Optic Neuritis:

(show top 50) (show all 5810)
# Title Authors PMID Year
Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. 54 61
20019228 2010
Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis. 54 61
19917985 2009
Association of the HLA-DPB1*0501 allele with anti-aquaporin-4 antibody positivity in Japanese patients with idiopathic central nervous system demyelinating disorders. 54 61
19140826 2009
A prominent elevation of glial fibrillary acidic protein in the cerebrospinal fluid during relapse in neuromyelitis optica. 61 54
18509235 2008
Neuromyelitis optica pathogenesis and aquaporin 4. 61 54
18510734 2008
Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. 54 61
12838519 2003
Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. 61 54
12732654 2003
Multiple MAG peptides are recognized by circulating T and B lymphocytes in polyneuropathy and multiple sclerosis. 61 54
11985632 2002
Multiple sclerosis is associated with enhanced B cell responses to the ganglioside GD1a. 61 54
10618693 1999
Augmented expression of tumour necrosis factor-alpha and lymphotoxin in mononuclear cells in multiple sclerosis and optic neuritis. 54 61
8624683 1996
Acute optic neuritis: myelin basic protein and proteolipid protein antibodies, affinity, and the HLA system. 61 54
8526468 1995
PCR typing of two short tandem repeat (STR) structures upstreams of the human myelin basic protein (MBP) gene; the genetic susceptibility in multiple sclerosis and monosymptomatic idiopathic optic neuritis in Danes. 61 54
9345452 1995
Increased mRNA expression of IL-10 in mononuclear cells in multiple sclerosis and optic neuritis. 54 61
7532318 1995
Optic neuritis and multiple sclerosis: the T cell repertoires to myelin proteins and MBP peptides change with time. 61 54
7524258 1994
Autoimmune T cell repertoire in optic neuritis and multiple sclerosis: T cells recognising multiple myelin proteins are accumulated in cerebrospinal fluid. 61 54
7515411 1994
Anti-myelin basic protein and anti-proteolipid protein specific forms of multiple sclerosis. 61 54
7510098 1994
Optic neuritis is associated with myelin basic protein and proteolipid protein reactive cells producing interferon-gamma, interleukin-4 and transforming growth factor-beta. 54 61
7507500 1994
Relative frequency of autoantibodies to myelin basic protein and proteolipid protein in optic neuritis and multiple sclerosis cerebrospinal fluid. 61 54
7510787 1994
Optic neuritis and multiple sclerosis: anti-MBP and anti-MBP peptide antibody-secreting cells are accumulated in CSF. 54 61
7513391 1993
T cells recognizing multiple peptides of myelin basic protein are found in blood and enriched in cerebrospinal fluid in optic neuritis and multiple sclerosis. 61 54
7680141 1993
Acute optic neuritis associated with immunization with the CNS myelin proteolipid protein. 54 61
1373123 1992
Expanding the phenotype of MOG antibody-associated disease (MOGAD): half a century of epilepsy and relapsing optic neuritis. 61
33148814 2021
Predictors of Visual Acuity and Usefulness of a Treatment Algorithm in Rhinogenous Optic Neuritis. 61
31550936 2021
Optic neuritis associated with sunitinib. 61
32914245 2021
Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis Presenting as Idiopathic Orbital Inflammatory Syndrome. 61
32108670 2021
Sjögren Disease and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis. 61
32235221 2021
Incidence Rates of Autoimmune Diseases in European Healthcare Databases: A Contribution of the ADVANCE Project. 61
33462778 2021
Predictive value of optical coherence tomography, multifocal visual evoked potentials, and full-field visual evoked potentials of the fellow, non-symptomatic eye for subsequent multiple sclerosis development in patients with acute optic neuritis. 61
32507033 2021
Shortened Pattern Electroretinogram Latency and Impaired Autoregulatory Dynamics to Steady-State Stimuli in Patients With Multiple Sclerosis. 61
31977664 2021
Comparison of macular structural and vascular changes in neuromyelitis optica spectrum disorder and primary open angle glaucoma: a cross-sectional study. 61
32430343 2021
Utilization of Visual Acuity Retroilluminated Charts for the Assessment of Afferent Visual System Dysfunction in a Pediatric Neuroimmunology Population. 61
32868561 2021
Myelin oligodendrocyte glycoprotein-IgG-positive, steroid-responsive combined central and peripheral demyelination with recurrent peripheral neuropathy. 61
33078247 2021
Comment on: Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment. 61
33608641 2021
Neurofilament results for the phase II neuroprotection study of phenytoin in optic neuritis. 61
33058438 2021
Optic neuritis after ocular trauma in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. 61
33591639 2021
Foveal changes in AQP4-Ab seropositive NMOSD are independent of optic neuritis and not overtly progressive. 61
33547839 2021
Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience. 61
33388560 2021
Visual deficits and cognitive assessment of multiple sclerosis: confounder, correlate, or both? 61
33590339 2021
Neuro-ophthalmologic manifestations of multiple sclerosis other than acute optic neuritis. 61
33412489 2021
Advances in ophthalmic structural and functional measures in multiple sclerosis: do the potential ocular biomarkers meet the unmet needs? 61
33278142 2021
Optical Coherence Tomography Angiography of Peripapillary Vessel Density in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Comparative Study. 61
33562808 2021
Challenges in multiple sclerosis diagnosis: Misunderstanding and misapplication of the McDonald criteria. 61
32162581 2021
Association of VEGFA, TIMP-3, and IL-6 gene polymorphisms with predisposition to optic neuritis and optic neuritis with multiple sclerosis. 61
33121296 2021
Bruch's membrane opening-minimum rim width: An alternative OCT biomarker study for multiple sclerosis. 61
33601900 2021
Cavernous Sinus Thrombosis related to Orbital Cellulitis Serious Complication to Prevent: a case report and literature review. 61
33532066 2021
The long-term outcome of MOGAD: An observational national cohort study of 61 patients. 61
33528851 2021
Jaundice and Thrombocytopenia in an acute abdomen with concurrent Appendicitis and spontaneous Rectal perforation: An unusual presentation of human leptospirosis. 61
33530876 2021
A widespread rash with optic neuritis. 61
33554354 2021
Association between Optic Neuritis and Inflammatory Bowel Disease: A Population-Based Study. 61
33578895 2021
The many faces of ocular syphilis: case-based update on recognition, diagnosis, and treatment. 61
33549544 2021

Variations for Optic Neuritis

ClinVar genetic disease variations for Optic Neuritis:

# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MT-ND4 NC_012920.1:m.11443A>C SNV Uncertain significance 523305 rs1556423952 MT:11443-11443 MT:11443-11443

Expression for Optic Neuritis

Search GEO for disease gene expression data for Optic Neuritis.

Pathways for Optic Neuritis

Pathways related to Optic Neuritis according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
12.83 TNF MT-ND6 MT-ND4 IL6 IL1B
Show member pathways
Show member pathways
Show member pathways
12.62 TNF IL6 IL1B IL10 CCR5
Show member pathways
12.61 TNF IL6 IL1B IL10 HLA-DRB1
Show member pathways
12.41 IL6 IL10 GFAP CNTF
13 12.34 TNF LTA IL6 HLA-DRB1
Show member pathways
12.34 TNF IL6 IL1B CXCL8
Show member pathways
Show member pathways
17 12.27 TNF IL6 IL1B IL10 HLA-DRB1
18 12.25 TNF IL6 IL1B CXCL8
Show member pathways
12.23 TNF IL6 IL1B IL10
Show member pathways
Show member pathways
22 12.1 TNF IL6 IL1B IL10 CXCL8
23 12.01 TNF LTA IL6 IL1B
24 12 TNF IL6 IL1B IL10 CXCL8
25 11.98 TNF LTA IL1B CXCL8
26 11.95 TNF IL6 IL1B CXCL8
27 11.94 TNF IL6 IL1B HLA-DRB1
28 11.92 TNF IL6 IL1B IL10 CXCL8
29 11.84 TNF LTA IL1B IL10
30 11.84 TNF IL6 IL1B HLA-DRB1 CXCL8
Show member pathways
33 11.8 TNF IL6 IL1B IL10
34 11.77 TNF PLP1 IL6 IL1B IL10 CXCL8
35 11.73 TNF LTA IL6 IL10
Show member pathways
37 11.69 TNF IL6 IL1B CXCL8
Show member pathways
11.68 TNF LTA IL6 IL1B IL10
39 11.67 MBP MAG BDNF
40 11.65 TNF IL6 IL1B IL10 CXCL8
41 11.64 TNF IL6 IL1B CXCL8
42 11.51 TNF IL6 IL1B
43 11.42 TNF IL6 IL1B IL10 CXCL8
44 11.41 TNF IL6 IL1B IL10
45 11.37 TNF IL6 IL1B IL10
47 11.35 TNF IL6 IL1B
48 11.33 TNF IL6 IL1B
49 11.32 TNF IL6 IL1B IL10 CXCL8 CCR5
50 11.12 TNF IL6 IL1B IL10 HLA-DRB1

GO Terms for Optic Neuritis

Cellular components related to Optic Neuritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.91 TNF LTA IL6 IL1B IL10 HLA-DRB1
2 external side of plasma membrane GO:0009897 9.72 TNF MOG HLA-DRB1 CCR5 AQP4
3 astrocyte end-foot GO:0097450 9.16 GFAP AQP4
4 compact myelin GO:0043218 8.96 MBP MAG
5 myelin sheath GO:0043209 8.92 PLP1 MPZ MBP MAG

Biological processes related to Optic Neuritis according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.18 LTA IL6 IL1B IL10 HLA-DRB1 DPYSL5
2 positive regulation of gene expression GO:0010628 10.01 TNF PLP1 IL6 IL1B CXCL8 CNTF
3 inflammatory response GO:0006954 9.91 TNF PLP1 IL6 IL1B CXCL8 CCR5
4 negative regulation of neuron apoptotic process GO:0043524 9.87 MAG IL10 CNTF BDNF
5 regulation of insulin secretion GO:0050796 9.83 TNF IL6 IL1B
6 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.83 TNF IL6 CNTF
7 positive regulation of DNA-binding transcription factor activity GO:0051091 9.83 TNF IL6 IL1B IL10
8 response to glucocorticoid GO:0051384 9.82 TNF IL6 IL10
9 positive regulation of interferon-gamma production GO:0032729 9.81 TNF LTA IL1B
10 positive regulation of interleukin-8 production GO:0032757 9.8 TNF IL6 IL1B
11 humoral immune response GO:0006959 9.79 TNF LTA IL6
12 myelination GO:0042552 9.77 PLP1 MPZ MBP
13 substantia nigra development GO:0021762 9.76 PLP1 MBP MAG
14 positive regulation of interleukin-6 production GO:0032755 9.76 TNF MBP IL6 IL1B
15 cellular response to lipopolysaccharide GO:0071222 9.73 TNF IL6 IL1B IL10 CXCL8 CCR5
16 positive regulation of JAK-STAT cascade GO:0046427 9.72 TNF IL6 IL10
17 cytokine-mediated signaling pathway GO:0019221 9.7 TNF IL6 IL1B IL10 CXCL8 CNTF
18 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.67 MBP IL10
19 response to molecule of bacterial origin GO:0002237 9.67 IL10 CXCL8
20 negative regulation of neurogenesis GO:0050768 9.67 TNF IL6 IL1B
21 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.66 TNF MBP
22 regulation of establishment of endothelial barrier GO:1903140 9.66 TNF IL1B
23 negative regulation of lipid storage GO:0010888 9.65 TNF IL6
24 endothelial cell apoptotic process GO:0072577 9.64 TNF IL10
25 axon ensheathment GO:0008366 9.63 PLP1 MBP
26 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.61 TNF LTA
27 negative regulation of cytokine production involved in immune response GO:0002719 9.61 TNF IL10
28 immune response GO:0006955 9.61 TNF MBP LTA IL6 IL1B IL10
29 positive regulation of fever generation GO:0031622 9.59 TNF IL1B
30 sequestering of triglyceride GO:0030730 9.58 TNF IL1B
31 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.58 TNF IL1B IL10
32 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.56 TNF IL1B
33 positive regulation of neuroinflammatory response GO:0150078 9.54 TNF IL6 IL1B
34 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 9.51 TNF LTA
35 vascular endothelial growth factor production GO:0010573 9.5 TNF IL6 IL1B
36 positive regulation of glial cell proliferation GO:0060252 9.02 TNF LTA IL6 IL1B GFAP

Molecular functions related to Optic Neuritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural constituent of myelin sheath GO:0019911 9.26 PLP1 MBP
2 growth factor activity GO:0008083 9.26 IL6 IL10 CNTF BDNF
3 cytokine activity GO:0005125 9.17 TNF LTA IL6 IL1B IL10 CXCL8
4 interleukin-6 receptor binding GO:0005138 9.16 IL6 CNTF

Sources for Optic Neuritis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....